Comparative Pharmacology
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus PRE PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus PRE PEN.
AMINOHIPPURATE SODIUM vs PRE-PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
Benzylpenicilloyl polylysine is a skin test reagent that elicits a wheal-and-flare response in penicillin-allergic individuals by binding to penicillin-specific IgE antibodies on mast cells, triggering histamine release.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
0.25 mL intradermal injection of a 1:100 dilution (0.25 mg/mL) for skin testing; if negative, proceed to 0.05 mL intradermal injection of 1:10 dilution (2.5 mg/mL).
None Documented
None Documented
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
Terminal elimination half-life: 0.5-1.0 hour in patients with normal renal function. Clinical context: Rapid elimination allows for short duration of action; half-life is prolonged in renal impairment.
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
Primarily renal excretion (60-80% as unchanged drug and metabolites). Biliary/fecal elimination accounts for <10%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent